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DONOR LYMPHOCYTE INFUSION FOR LATE RELAPSE FOLLOWED BY KIDNEY TRANSPLANTATION FOR
END-STAGE RENAL FAILURE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION FOR CHRONIC
MYELOID LEUKEMIA
A 36-year-old man was diagnosed in 1986 with chronic phase
(CP) chronic myeloid leukemia (CML). Three months later, he
developed a blast crisis and blastic embolization of his left tibial
artery requiring a left foot amputation. After successful induc-
tion and consolidation therapy, the patient (then in second CP)
underwent an allogeneic bone marrow transplantation (BMT)
from his human leukocyte antigen-identical brother. The con-
ditioning regimen consisted of cyclophosphamide, cytarabine,
and 8-Gy total body irradiation, and graft-versus-host disease
(GVHD) prophylaxis was carried out with cyclosporine A alone.
The immediate posttransplant course was complicated by grade
3 GVHD that was successfully treated with steroids and meth-
otrexate, and the patient was discharged on day 43. At that
time, his serum creatinine was 16 mg/L (Fig. 1). Limited chronic
GVHD was diagnosed on day 100 and was successfully treated
with psoralen and long-wave ultraviolet radiation. Thereafter,
the evolution remained uneventful except for hypertension. Al-
though cyclosporine A was discontinued on day 420, his renal
function progressively degraded (Fig. 1). In 1994, the patient’s
serum creatinine was 32 mg/L and a renal biopsy revealed
tubulointerstitial nephritis with nephrosclerosis. Gradual dete-
rioration of his renal function resulted in the institution of
maintenance hemodialysis in August 1996. A kidney transplant
from his marrow donor brother was considered in March 1998.
However, the patient’s bone marrow analysis at that time
showed a cytogenetic relapse (4 of 26 phi-positive metaphases)
and mixed chimerism. He thus received donor lymphocyte in-
fusion (DLI) (1107 CD3 cells/kg). The patient did not expe-
rience acute or chronic GVHD, and bone marrow analyses 3 and
7 months later showed a complete cytogenetic and molecular
response. Chimerism analysis in December 1999 demonstrated
full donor chimerism.
After his brother, who had given bone marrow to him 14
years earlier, was found to be an acceptable donor, kidney
transplantation was performed in April 2000, without any
immunosuppressive therapy. The transplanted kidney func-
tioned immediately, and a kidney biopsy performed 6 months
after the transplant did not show any sign of graft rejection
(Fig. 1). Now, more than 2 years after kidney transplanta-
tion, the patient is well with normal renal function and
without any sign of GVHD or CML.
Although late-onset renal failure occurs in up to 20% of sur-
vivors of allogeneic bone marrow transplantation, chronic renal
failure requiring dialysis is a relatively rare event in the BMT
setting (approximately 2% of the patients) (1). The feasibility of
kidney transplantation after allogeneic BMT has already been
reported (2–4). However, our report is unique in that the pa-
tient was in relapse when the kidney transplant procedure was
contemplated but could be rescued by a DLI.
It is now well established that DLI can cure CML in pa-
tients relapsing after an allogeneic transplant (5). Because
leukemic relapse may be accompanied by residual host he-
matopoiesis that would imply a requirement for restoration
of immunosuppressive therapy to avoid kidney graft rejection
and thereby alter the DLI-mediated graft-versus-leukemia
effect, we decided to delay kidney transplantation until well
after DLI and achievement of full donor chimerism. In con-
clusion, our report emphasizes that renal transplantation
should not be ruled out in patients with DLI-sensitive dis-
ease relapsing after an allogeneic BMT.
FIGURE 1. Evolution of serum creatinine (continuous
line) and creatinine clearance (broken line) through-
out the posttransplant course.
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MIXED CHIMERISM OF THYROID FOLLICLE CELLS AFTER ALLOGENEIC BONE MARROW
TRANSPLANTATION
Recently, a growing amount of data have been accumu-
lated concerning the plasticity of human adult stem cells
that may generate a multilineage engraftment. In this
context, there is some evidence of a putative relationship
between mixed microchimerism in thyroid follicle cells (1)
of presumed fetal origin and autoimmune disease in fe-
male patients (2– 4). A model to study this issue would
include patients in whom bone marrow transplantations
(BMTs) with a sex-mismatched constellation were per-
formed. Therefore, a retrospective analysis of thyroid
gland tissue derived from four male patients with chronic
myelogenous leukemia who underwent allogeneic BMTs
was performed. These patients received full unmanipu-
lated grafts (median size 2.3108/kg nucleated cells) from
sex-mismatched human leukocyte antigen-identical (fe-
male) family donors following standard procedures that
included conditioning regimens (Cy 60 mg/kg/day2; dose
of total body irradiation 42.5 Gy 60 cobalt) and graft-
versus-host-disease prophylaxis (short-term methotrexate
cyclosporine A). Leukemic relapse occurred in two pa-
tients after a posttransplant observation time ranging
from 2 to 26 months. Relevant grades of acute graft-ver-
sus-host-disease accompanied by lethal infections devel-
oped in the other two patients of this series approximately
3 to 12 weeks after BMT. As controls, postmortem tissue
samples without evidence of thyroid pathology were ob-
tained from two male and two female patients.
During the autopsy, samples of thyroid gland tissue
were randomly taken from the right and left lobes and
fixed in buffered 5% formalin. For dual-color genotypic
evaluation, paraffin-embedded sections were used and pro-
cessed by a previously described modified fluorescence in
situ hybridization (FISH) technique applying x- and y-
chromosome probes (5). To neutralize possible artefacts in
the autopsy material and to match with the obstacles of a
certain plane of section regarding proper signal recogni-
tion, only cells were evaluated that displayed two distinc-
tive red and green dots.
After FISH, distinctively labeled thyroid epithelial cells
lining the walls of the colloid-containing follicles were easily
identifiable. In each of the four patients of the control group,
300 follicle cells were counted; however, FISH failed to reveal
any sex-mismatched chromosome signals in this cohort. Con-
trasting this finding in the four patients with a history of
BMT, a striking, although quantitatively low, number of
thyroid epithelium displayed mixed microchimerism (Table
1). It is noteworthy that this small amount of female donor
cells among the host-type (male) thyroid follicle cells was not
related to the period of engraftment.
Considering the negative findings in the control group of
patients, sensitivity of the FISH technique seems to be
TABLE 1. Mixed chimerism of the thyroid follicle cells in a
sex-mismatched (host male, donor female) allogeneic bone
marrow transplantation constellation (percentages are
listed in brackets)





1 354 331 23 (6.5)
2 387 369 18 (4.7)
3 349 331 18 (5.2)
4 626 606 20 (3.2)
Total 1,716 1,637 79 (4.6)
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